"Designing Growth Strategies is in our DNA"

Radiotheranostics Market Size, Share & Industry Analysis, By Radioisotope (Lutetium-177, Radium-223, Iodine-131, and Others), By Application (Neuroendocrine Tumors, Prostate Cancer, and Others), By End-User (Hospitals & Clinics, Diagnostic Centers, and Others), and Regional Forecast, 2025-2032

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI108932

 


To get information on various segments, share your queries with us

ATTRIBUTE

DETAILS

Study Period

2019-2032

Base Year

2024

Estimated Year

2025

Forecast Period

2025-2032

Historical Period

2019-2023

Unit

Value (USD Billion)

Growth Rate

CAGR of 28.7% from 2025-2032

Segmentation

By Radioisotope

  • Lutetium-177
  • Radium-223
  • Iodine-131
  • Others

By Application

  • Neuroendocrine Tumors
  • Prostate Cancer
  • Others

By End-User

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

By Region

  • North America (By Radioisotope, Application, End-User, and Country)
    • U.S.
    • Canada
  • Europe (By Radioisotope, Application, End-User, and Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Radioisotope, Application, End-User, and Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Rest of the World (By Radioisotope, Application, End-User, and  Country/Sub-Region)

 

Radiotheranostics Market
  • 2019-2032
  • 2024
  • 2019-2023
  • 125
  • Buy Now

    (Offer valid till 15th Dec 2025)

Download Free Sample

    man icon
    Mail icon
    Captcha refresh
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports